Pay in 4 interest-free payments of $5.95 Learn more
Ships within 48 hours · Estimated delivery Aug 19 - Aug 24
Receptor profile (research literature): GLP-1R: potent agonist (cAMP EC50 0.775 nM per Coskun et al., 2022) GIPR: potent agonist (cAMP EC50 0.064 nM per Coskun et al., 2022) Glucagon receptor: agonist (cAMP EC50 5.79 nM per Coskun et al., 2022) this is the key differentiator from tirzepatide The published Coskun 2022 characterization describes retatrutide as showing balanced GCGR and GLP-1R activity with comparatively more GIPR potency
Insurance coverage transitions can disrupt ongoing therapy
Phase 2 data showed up to 24.2% weight loss at 48 weeks, the highest ever recorded for any obesity medication
Not to mention a fringe benefit: she feels society treats her better now that she lives in a smaller body
73 Conservative medical therapy has a good outcome when prognostic scoring systems point against proceeding with transplant, and it appears that physicians are making better-informed decisions in regards to transplantation of patients who present with acute liver failure related to APAP hepatotoxicity
The glucagon-like peptides
